Finance

Beta
Lists
CLLS:NASDAQ
Cellectis SA
$3.30
+12.44%
(+0.36) 1D
Jul 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CLLS...
Open
$3.31
High
$3.39
Low
$3.21
Mkt. cap
234.38M
Avg. vol.
46.16K
Volume
32.82K
52-wk high
$5.48
52-wk low
$1.56
EPS
-$0.67
Beta
2.88
Shares outstanding
72.09M
No. of employees
227
Open
$3.31
High
$3.39
Low
$3.21
Mkt. cap
234.38M
Avg. vol.
46.16K
Volume
32.82K
52-wk high
$5.48
52-wk low
$1.56
EPS
-$0.67
Beta
2.88
Shares outstanding
72.09M
No. of employees
227
News stories
From sources across the web
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA
CEOAndré Choulika
Employees227
Founded1999
Headquarters-
SectorBiotechnology
Websitecellectis.com
Analyst ratings
Based on 1 analyst giving stock ratings to CLLS in the past 3 months
Buy
Buy
1
Hold
0
Sell
0
12-month forecast
Based on 1 Wall Street analyst offering 12-month price targets for CLLS in the last 3 months
Highest
Current $3.30
$9.00 (+172.73%)
Average
$9.00 (+172.73%)
Lowest
$9.00 (+172.73%)
Analyst
Recommendation
Action
Price target
Projected
Date
Gena Wang
Barclays
Buy
Initiated
$9.00
+172.7%
05/28/2026
William Maughan
Clear Street
Buy
Maintained
$9.00
+172.7%
03/20/2026
Yanan Zhu
Wells Fargo
Hold
Maintained
$4.00
+21.2%
01/13/2026
Soumit Roy
JonesTrading
Hold
Maintained
-
-
11/11/2025
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
18.19M
37.16M
12.21M
7.55M
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
23.08M
24.07M
24.44M
27.19M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.08M
5.21M
4.80M
5.59M
Operating expense
27.78M
29.12M
29.56M
32.72M
Total operating expenses
27.78M
29.12M
29.56M
32.72M
Operating income
-9.59M
8.04M
-17.35M
-25.17M
Other non operating income
-282.00K
-7.06M
-8.80M
5.90M
EBT including unusual items
-23.74M
589.00K
-26.74M
-17.72M
EBT excluding unusual items
-23.74M
589.00K
-26.74M
-17.72M
Income tax expense
-
-
-423.00K
46.00K
Effective tax rate
-
-
1.58%
-0.26%
Other operating expenses
-378.00K
-154.00K
320.00K
-63.00K
Net income
-23.74M
589.00K
-26.32M
-17.76M
Net profit margin
-130.46%
1.58%
-215.60%
-235.36%
Earnings per share
-0.22
0.02
-0.24
-
Interest and investment income
2.20M
2.31M
2.08M
1.84M
Interest expense
-2.06M
-2.11M
-2.03M
-1.93M
Net interest expenses
139.00K
206.00K
44.00K
-83.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-6.46M
11.16M
-15.33M
-22.13M
Gain or loss from assets sale
-
-
-
-5.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer